# The Effects of Allicor on Patients After Revascularization Treatment During a Year

Study · id `cardio:ct-nct05813171` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05813171](<https://clinicaltrials.gov/study/NCT05813171>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05813171

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05813171. Randomized; double masking; primary purpose treatment. Start 2023-04-20 (anticipated); primary completion 2024-04-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05813171, source copy `cardio:ctgov-nct05813171-2023-04-19`, retrieved 2026-10-31)
- Planned start: 2023-04-20 (anticipated) (ClinicalTrials.gov record NCT05813171, source copy `cardio:ctgov-nct05813171-2023-04-19`, retrieved 2026-10-31)
- Primary completion: 2024-04-20 (anticipated) (ClinicalTrials.gov record NCT05813171, source copy `cardio:ctgov-nct05813171-2023-04-19`, retrieved 2026-10-31)
- Completion: 2024-05-31 (anticipated) (ClinicalTrials.gov record NCT05813171, source copy `cardio:ctgov-nct05813171-2023-04-19`, retrieved 2026-10-31)
- Countries: Russia (ClinicalTrials.gov record NCT05813171, source copy `cardio:ctgov-nct05813171-2023-04-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05813171-2023-04-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Effects of Allicor on Patients After Revascularization Treatment During a Year
- Acronym: TEA-PARTY
- Condition: Atherosclerosis
- Condition: Peripheral Arterial Disease
- Intervention (Dietary supplement): Allicor
- Intervention (Drug): Placebo
- Lead sponsor: Institute for Atherosclerosis Research, Russia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Institute for Atherosclerosis Research, Russia (`cardio:org-institute-for-atherosclerosis-research-russia`)

## Provenance

Content hash: 2e14841a89f8b3296b9e72d6dee8d8a7e491bd954b99172c8d683e0bb2cebb73
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
